Improving chances for successful clinical outcomes with better preclinical models

Heather Wenzel, Robert W. Kaminski, Kristen A. Clarkson, Milton Maciel, Mark A. Smith, Weiping Zhang, Edwin V. Oaks

Research output: Contribution to journalArticlepeer-review


In order to avoid expensive clinical failures, better and more predictive animal models of vaccine efficacy are needed to screen Shigella and ETEC vaccine candidates for protective efficacy. The 2016 Vaccines Against Shigella and ETEC (VASE) Conference included a workshop focused on the strengths and weaknesses of current models, particularly in terms of the correlation to vaccine efficacy in human clinical trials. Workshop presenters shared information on existing preclinical animal models for assessing the immunogenicity and protective efficacy of Shigella and ETEC vaccines. The presentations were followed by a discussion about how to best utilize these models, how the models can be improved, and best practices for Shigella and ETEC vaccine developers. The workshop concluded with three major recommendations for the field: (1) develop better and more consistent reagents for animal studies and make them widely available, (2) prioritize harmonization of animal models and immunology assays, and (3) develop preclinical correlates of protection, which will be key in selecting the best vaccine candidates for further clinical development.

Original languageEnglish (US)
Pages (from-to)6798-6802
Number of pages5
Issue number49
StatePublished - Dec 14 2017
Externally publishedYes


  • Animal models
  • Challenge model
  • ETEC
  • Enterotoxigenic Escherichia coli
  • Preclinical
  • Shigella

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Improving chances for successful clinical outcomes with better preclinical models'. Together they form a unique fingerprint.

Cite this